肿瘤浸润淋巴细胞
临床试验
医学
癌症
癌症治疗
肿瘤科
重症监护医学
免疫疗法
内科学
作者
Hyun Lee,Kwanghee Kim,Jin Chung,Mofazzal Hossain,Min Cheol Chang
出处
期刊:BioEssays
[Wiley]
日期:2023-05-11
卷期号:45 (7)
标识
DOI:10.1002/bies.202200204
摘要
Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach for treating refractory or advanced solid cancers by using autologous TILs harvested from cancer tissues. Despite the heterogeneity of cancer, TIL therapy can potentially produce a positive therapeutic response, including complete remission. After decades of research on lymphocyte functions, culture/expansion methods, therapeutic protocols, and multiple clinical trials, TIL therapy has finally reached a stage where it can be formally approved for clinical use. TIL therapy is expected to hold a unique position among anti-cancer therapeutic options as a standard intervention. To successfully introduce TIL therapy into clinical settings, there is a need to expand therapeutic indications and set up the best protocols for cancer tissue sampling and manufacturing, and related clinical trials. Moreover, studies on next-generation TIL therapy have already begun, and post-approval real-world data will promote and support further research.
科研通智能强力驱动
Strongly Powered by AbleSci AI